Citigroup Inc. lifted its position in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 161.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 139,875 shares of the biotechnology company’s stock after acquiring an additional 86,347 shares during the quarter. Citigroup Inc. owned approximately 0.39% of Five Prime Therapeutics worth $1,301,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Quantamental Technologies LLC purchased a new stake in shares of Five Prime Therapeutics in the 4th quarter valued at approximately $58,000. Virtu Financial LLC purchased a new stake in shares of Five Prime Therapeutics in the 4th quarter valued at approximately $113,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Five Prime Therapeutics in the 3rd quarter valued at approximately $190,000. Jefferies Group LLC purchased a new stake in shares of Five Prime Therapeutics in the 3rd quarter valued at approximately $191,000. Finally, BlueMountain Capital Management LLC increased its stake in Five Prime Therapeutics by 398.9% in the 3rd quarter. BlueMountain Capital Management LLC now owns 14,766 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 11,806 shares during the period. Institutional investors and hedge funds own 86.30% of the company’s stock.
Several research analysts have weighed in on the stock. Cowen reiterated a “buy” rating on shares of Five Prime Therapeutics in a research note on Wednesday, February 27th. BidaskClub upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 22nd. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, January 21st. Wedbush upgraded shares of Five Prime Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research note on Thursday, January 17th. Finally, ValuEngine lowered shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 4th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $24.29.
Five Prime Therapeutics stock opened at $12.72 on Friday. The company has a market capitalization of $451.40 million, a price-to-earnings ratio of -3.08 and a beta of 3.16. Five Prime Therapeutics Inc has a twelve month low of $7.84 and a twelve month high of $19.95.
Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($1.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.32) by $0.20. Five Prime Therapeutics had a negative net margin of 281.64% and a negative return on equity of 44.55%. Equities research analysts expect that Five Prime Therapeutics Inc will post -3.99 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Five Prime Therapeutics Inc (FPRX) Shares Bought by Citigroup Inc.” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2019/03/17/five-prime-therapeutics-inc-fprx-shares-bought-by-citigroup-inc.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
Featured Article: What are Closed-End Mutual Funds?
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.